Bushu Pharma provides contract manufacturing services for the production of granules, powders, tablets and capsules, Plain tablets, Film-coated tablets, Sugar-coated tablets, Multi-layer tablets, Orally disintegrating tablets, Hard capsules and more
Our recently launched Gateway to Asia service allows you to import bulk products into Japan for quality inspection, labeling, packaging and distribution across Japan and to other Asian countries. Cut down on lead time and inventory management with our Asia Hub Solution.
Ensuring your product has no defects is essential to your success in any market. Bushu Pharma has built its expertise in Visual Inspection. We have the know-how and equipment to expertly conduct inspection of your product – checking for visual defects of both the product and packaging.
We accommodate the strong expansion of temperature-controlled bio-pharmaceuticals (2 to 8°C) for the global markets. One is Misato Cold Chain Center (498 pallets), the new cold chain center for packaging & storage, and another is Kawagoe Cold storage warehouse (500 pallets).
Japan’s premier contract manufacturing organization.
Offering the best in Pharmaceutical Manufacturing & Supply Chain solutions.
Proven Track-record + Global Capabilities
Years as CMO
GMP Global Certifications
Percent International Sales
One of the world’s largest and most trusted providers of business sustainability ratings, EcoVadis – has recently confirmed that Bushu Pharma has met the standards necessary to receive their CSR award medal and certification.
Today, construction of the Misato Cold Chain Center (temperature-controlled facility) was successfully completed, and a ceremony was held to celebrate the occasion. The work was completed on time, thanks to the support of the construction company, the subcontractors, and all of the other related parties.
In response to requests for a professional contract development and manufacturing organization (CDMO) partner in Asia that can better meet the needs and challenges of the global market, Bushu Pharma has appointed Mr. Koichiro Matsumoto as President and CEO of the company as of July 6 2020
Bushu Pharmaceuticals announced on August 14 a major capital program costing $100 million to expand its footprint, capacity and portfolio of services. The program extends over the next five years in order to accommodate client needs.